The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs.
The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded.…
Customers have complained that a telehealth network selling compounded GLP-1s has been ripping them off—even after it had to pay…
The FDA said on Friday it plans to restrict GLP-1 ingredients used in non-approved compounded drugs from companies like Hims &…
Within 24 hours of injecting the first dose of a weight loss medication she received following a visit with a telehealth doctor,…
Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded.
